Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics announced the closing of its public offering of 1,100,000 shares at $1.00 per share, raising approximately $1.1 million. The funds will support the development of their ONP-002 product candidate and cover general corporate expenses. Dawson James Securities acted as the sole placement agent, and the offering was made under a shelf registration statement filed with the SEC. Legal representation was provided by Shumaker, Loop & Kendrick, LLP for Oragenics and ArentFox Schiff LLP for the placement agent.
Oragenics, a company focused on developing intranasal pharmaceuticals for neurological disorders, announced the pricing of a public offering. The company plans to offer 1,100,000 shares of its common stock at $1.00 per share, aiming to raise around $1.1 million before costs. The closing date is expected on or about June 26, 2024, pending customary conditions. The net proceeds will fund the development of Oragenics' product candidate ONP-002, along with other corporate purposes and working capital. Dawson James Securities is the sole placement agent for this offering. This offering is made under a shelf registration statement filed and declared effective by the SEC. Interested investors should read the full prospectus available on the SEC website.
Oragenics, Inc. (NYSE: OGEN), a company focused on intranasal pharmaceuticals for neurological disorders, announced a proposed public offering of its common stock or pre-funded warrants.
All securities in the offering will be sold by Oragenics. The proceeds will fund the development of its ONP-002 product candidate and cover general corporate expenses. Dawson James Securities, Inc. will serve as the sole placement agent.
The offering is being made under a shelf registration statement filed with the SEC. The terms will be detailed in a prospectus supplement available on the SEC's website.
The completion of the offering is subject to market conditions, and there's no assurance on its size or terms.
Oragenics (NYSE American: OGEN) announced that the NYSE American has accepted its compliance plan, allowing it to remain listed. The company has until October 18, 2025, to regain compliance with the exchange's standards. Quarterly monitoring will be conducted to ensure progress. Failure to meet these requirements may result in delisting proceedings.
Oragenics has appointed Dr. William “Frank” Peacock as Chief Clinical Officer, with a focus on conducting a Phase II clinical trial for ONP-002, a drug aimed at treating concussions in the Emergency Department. Dr. Peacock, a renowned emergency medicine expert, will oversee this trial in collaboration with Avance Clinical. Previous Phase I trials indicated ONP-002 is safe and well-tolerated. The trial aims to assess biomarkers and symptom severity post-concussion. Concussions, affecting 69 million people globally each year, remain a critical unmet medical need. Dr. Peacock's extensive background in emergency medicine and concussion research is expected to be pivotal for the success of this trial.
Oragenics announced a webinar on neurotrauma medicine to be held on May 20, 2024, at 12:00 PM ET. The webinar will focus on Traumatic Brain Injury (TBI), its causes, and its links to long-term neurological disorders. The company will discuss their lead drug candidate, ONP-002, a neurosteroid for mild TBI, and present outcomes from preclinical and Phase I trials. Details of the forthcoming Phase II trial in acute and emergency departments will also be covered. Expert speakers include Dr. James P. Kelly and Dr. Frank Peacock IV.
Oragenics (NYSE American: OGEN) announced preparations for a Phase II clinical trial of its lead drug candidate, ONP-002, designed to treat mild Traumatic Brain Injury (mTBI). The trial will focus on intranasal delivery for rapid brain targeting, bypassing the blood-brain barrier. Oragenics has optimized the drug formulation and secured intranasal devices, partnering with Avance Clinical to implement the trial in emergency departments of level one trauma centers. Preclinical studies showed promising results in brain injury outcomes, and Phase I trials confirmed ONP-002's tolerability in humans. Concussions, a significant global health issue, often lead to long-term neurological disorders, highlighting the need for effective treatments like ONP-002.
Oragenics, Inc. partners with Avance Clinical for a Phase II clinical trial in Australia to evaluate ONP-002 for mild Traumatic Brain Injury (TBI). The partnership aims to address the significant unmet medical need for concussion treatment through innovative intranasal pharmaceuticals. Oragenics' lead drug candidate, ONP-002, has shown promise in a Phase I trial and is delivered through a unique intranasal device designed for direct brain delivery. Avance Clinical's expertise in managing clinical trials in Australia, New Zealand, and North America brings valuable experience to the collaboration, highlighting the potential for future concussion treatment protocols.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
